• PureTech’s founded entity Celea Therapeutics will present deupirfenidone data at the European Respiratory Society Congress in Barcelona on Sept. 5-9, 2026.
• Phase 3 SURPASS-IPF trial design will be presented on Sept. 6, 2026, comparing deupirfenidone 825 mg TID versus pirfenidone 801 mg TID.
• Phase 1 drug-interaction results with nintedanib will be presented on Sept. 7, 2026, indicating clinically relevant interactions are unlikely.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202608250705BIZWIRE_USPR_____20260825_BW334873) on August 25, 2026, and is solely responsible for the information contained therein.